- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01184079
Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting
The investigators propose a randomized, open label trial of the immunogenicity of HPV vaccine among males 18-24 years old, comparing an on-time administration of the third dose with delayed administration of the third dose. All participants would receive the first and second doses according to schedule. They would be randomized to either Dose 3 at 6 months or Dose 3 at 12 months.
Hypothesis: The Geometric mean titers in the 12 month test group (T) are non-inferior to the usual timing control group (C):
H0: δ ≤ -δ0 versus H1: δ > -δ0 where δ = log (GMTT )- log (GMTC) and δ0 is the pre-specified non-inferiority margin
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
1. Specific Aims and Overview: The investigators propose a randomized, open label trial of HPV vaccine among males 18-24 years old, comparing an on-time administration of the third dose with delayed administration of the third dose. All participants would receive the first and second doses according to schedule. They would be randomized to either Dose 3 at 6 months or Dose 3 at 12 months.
Blood would be drawn for titers at twice from all participants: pre-dose 1 and one month post Dose 3.
No cytology studies or DNA studies will be conducted.
1.1 Aims:
- Determine if delay in the third dose is immunologically non-inferior to the standard administration schedule (1 month post-dose 3).
- Determine the side effect profile of a delayed third dose, in comparison to the standard schedule.
- Determine the preference and compliance of the men for the timing of the third dose.
1.2 Hypothesis for non- inferiority:
The GMTs in the test group (T) are non-inferior to the usual timing control group (C):
H0: δ ≤ -δ0 versus H1: δ > -δ0 where δ = log (GMTT )- log (GMTC) and δ0 is the pre-specified non-inferiority margin.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15261
- University of Pittsburgh
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Males age 18-26
Exclusion Criteria:
- Hospitalization within the past year
Previous HPV vaccination
>/=5 sexual partners (i.e., insertive intercourse) No other drug studies within 30 days of proposed HPV vaccination
- History of genital warts
- Immunosuppression
- Other vaccines within 8 days of proposed HPV vaccination
- Hypersensitivity to yeast or HPV vaccine components
- Known autoimmune disorders
- Receipt of immunoglobulins or blood product within 90 days of enrollment (may defer until 90 days completed)
- Serious Adverse Reaction to HPV vaccine
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: 12 months
Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine
|
0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
Andre navne:
0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
Andre navne:
|
Aktiv komparator: 6 month
Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine
|
0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
Andre navne:
0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Immunogenicity After Dose 3
Tidsramme: 1 month after dose 3 (e.g., month 7 if third dose at 6months or month 13 if third dose at 12 months)
|
Geometric mean titer (GMT) and 95% confidence intervals around titer 1 month after dose 3 in per protocol population, comparing the two groups.
|
1 month after dose 3 (e.g., month 7 if third dose at 6months or month 13 if third dose at 12 months)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Compliance With 3rd Dose
Tidsramme: at 3rd dose (i.e., at month 6 or month 12, depending on arm)
|
Determine the compliance of the men for the timing of the third dose.
|
at 3rd dose (i.e., at month 6 or month 12, depending on arm)
|
Safety Profile
Tidsramme: 1 week after vaccination
|
Total proportion of side effects reported after any dose, compared by arm.
|
1 week after vaccination
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Richard K Zimmerman, MD MPH, University of Pittsburgh
Publikationer og nyttige links
Generelle publikationer
- Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E, Cost G, Hand L, Hayes J, Michaels M. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health (Larchmt). 2010 Aug;19(8):1441-7. doi: 10.1089/jwh.2009.1753.
- Lin CJ, Zimmerman RK, Nowalk MP, Huang HH, Raviotta JM. Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males. Vaccine. 2014 Feb 3;32(6):693-9. doi: 10.1016/j.vaccine.2013.11.098. Epub 2013 Dec 14.
- Zimmerman RK, Lin CJ, Raviotta JM, Nowalk MP. Do vitamin D levels affect antibody titers produced in response to HPV vaccine? Hum Vaccin Immunother. 2015;11(10):2345-9. doi: 10.1080/21645515.2015.1062955.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IISP#38206
- PRO10070407 (Anden identifikator: University of Pittsburgh IRB)
- I#0021806 (Anden identifikator: University of Pittsburgh InfoEd)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Quadrivalent HPV Vaccine
-
H. Lee Moffitt Cancer Center and Research InstituteAktiv, ikke rekrutterendeHPV-vaccine | HPVForenede Stater, Puerto Rico
-
Indiana UniversityMerck Sharp & Dohme LLCAfsluttetHPV-vaccine holdninger | HPV-vaccine hensigtForenede Stater
-
Global Alliance to Immunize Against AIDS Vaccine...Merck Sharp & Dohme LLCAfsluttetHPV-relateret livmoderhalskræft | HPV
-
Beijing Chaoyang District Centre for Disease Control...UkendtQuadrivalent influenzavirusvaccine
-
Emory UniversityRekruttering
-
East Carolina UniversityRekruttering
-
University of FloridaNational Cancer Institute (NCI)Aktiv, ikke rekrutterende
-
University of MinnesotaAfsluttet
-
Beijing Chaoyang District Centre for Disease Control...AfsluttetQuadrivalent influenzavirusvaccineKina
-
Memorial Sloan Kettering Cancer CenterHackensack Meridian Health; The City College of New YorkAktiv, ikke rekrutterendeForsøg med en social marketingkampagne for at øge HPV-vaccination blandt mexicanske amerikanske børnHPV-vaccinationForenede Stater
Kliniske forsøg med quadrivalent human papillomavirus vaccine
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AfsluttetHIV-infektioner | Seksuelt overførte sygdommeForenede Stater, Puerto Rico
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeHumant papillomavirus-relateret cervikal karcinomCosta Rica
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; University of Arkansas og andre samarbejdspartnereAfsluttetPrecancerøs tilstand | Anal kræft | Peniskræft | Ikke-neoplastisk tilstandForenede Stater, Puerto Rico
-
PATHNational Institute of Hygiene and Epidemiology, VietnamAfsluttetDosisskemaundersøgelseVietnam
-
Universidad Nacional Autonoma de MexicoMerck Sharp & Dohme LLC; Secretaria de Salud, MexicoUkendtHuman Papilloma VirusMexico
-
Johns Hopkins Bloomberg School of Public HealthMerck Sharp & Dohme LLC; Universidad Peruana Cayetano Heredia; NGO Via LibreAfsluttetHuman papillomavirus infektionPeru
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCAfsluttetInfektion | Precancerøs tilstandForenede Stater
-
Medical College of WisconsinM.D. Anderson Cancer Center; National Cancer Institute (NCI); The University...Afsluttet
-
Beijing Health Guard Biotechnology, IncNational Institutes for Food and Drug Control, China; Jiangsu Province... og andre samarbejdspartnereAfsluttetHuman Papilloma Virus InfektionKina
-
Beijing Health Guard Biotechnology, IncAktiv, ikke rekrutterende